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community-dwelling patients with diabetes aged between 20 and 85 in the 2006 and 
2007 Medical Expenditure Panel Survey (MEPS) consolidated data ﬁ les, a nationally 
representative survey linked to prescribed medicines ﬁ le. The main outcome measure 
was the total expenditures including inpatient and ambulatory care, excluding phar-
macy costs, in 2006 and 2007, respectively. The differences in the health-care costs 
between statin users and nousers were estimated from the interaction terms between 
time trend and statin use, using a generalized linear model with a log link and gamma 
distribution, controlling for the difference in the two groups and time trend. The other 
covariates included were socioeconomic variables, insurance status, and comorbid 
conditions. RESULTS: In 2006, the median total expenditures of the statin users and 
nonusers were $1787 (IQR $583–5993) and $1117 (IQR $215–5565), respectively. 
In the subsequent year, the median total expenditures of the statin users and nonusers 
were $1452 (IQR $443–6354) and $851 (IQR $180–4451), respectively. No statisti-
cally difference in the total expenditures between the two groups was found (param-
eter estimate 0.37, 95% CI −0.05, 0.79, P-value 0.086). CONCLUSIONS: No 
evidence supporting the reduction in health-care resource utilization following statin 
use was found. While our ﬁ nding shows that statin use did not lower subsequent 
health-care resource utilization, further research is needed to investigate the potential 
effect of the differences among the users and nonusers, and the potential effect of the 
differential slopes of the two groups on resource utilization overtime. 
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WHICH STRATEGY CAN CONTROL THE EXPENDITURE OF 
HIGH-PRICE DRUGS?
Sooksriwong CO
Mahidol University, Bangkok, Thailand
OBJECTIVES: To compare patients’ expenditure on utilization of high price new 
statin drugs. METHODS: This is a cross-sectional analysis. The hospital database of 
out-patients diagnosed as hyperlipidemia during 2003–2006 was retrieved for drug 
names and their costs. The expenditure for statin drugs per patient before and after 
a new statin was prescribed were compared. RESULTS: Before Fluvastatin 80 mg was 
included to the hospital formulary in 2003, the expenditure for statin drugs per patient 
was 8.27 USD. Average statins expenditure after 3 months of Fluvastatin 80 mg ﬁ rst 
prescribed was increased to be was 22.59 USD or 273%, with the market share only 
0.4% of all antihyperlipidemic drugs prescribed in the hospital. When other statins, 
Pravastatin 40 mg, Atorvastatin 40 mg, Simvastatin 80 mg, Rosuvastatin 10 mg, and 
Pravastatin 20 mg; were included to a hospital formulary, the expenditure for statin 
drugs per patient were changed to +7%, +151%, −24%, +169, and −26%, respec-
tively; while the market share for each drug at the time of ﬁ rst prescribe was 1.9%, 
0.4%, 0.2%, 2.8%, and 1.0% respectively. It was found that when a new statin with 
the same generic name but different strength was prescribed, the average statin expen-
diture was reduced; while new generic statins increased the expenditure. The average 
cost of statins per patient after including Pravastatin 20 mg to the formulary in 2006 
was US$45.02; which was 544% of the baseline statins cost in 2003. CONCLU-
SIONS: The hospital administrator should employ effective strategies to control uti-
lization of high price drugs; also prevent excessive drug promotion. 
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ANTI-THROMBOLYTIC AGENT USE AND PATTERNS OF HEALTH-CARE 
UTILIZATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
(AMI) USING KOREA NATIONAL HEALTH INSURANCE CLAIMS 
DATABASE
Choi J1, Jang EJ1, Suh HS1, Song H1, Choi DH2, Kim JS2, Lee SM1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea; 
2Yonsei University College of Medicine, Seoul, South Korea
OBJECTIVES: To the estimate the health-care utilization patterns and costs related 
to ST-elevation acute myocardial infarction(STEMI) and understand the pattern of 
anti-thrombolytic use after stenting with a Korean population based design. 
METHODS: We extracted the insurance claims records of STEMI patients deﬁ ned as 
diagnosed with AMI and admitted by emergency room from Korea National Health 
Insurance claims database. We examined the health-care service provided to stent naïve 
patients among STEMI patients deﬁ ned as having no coronary-stents during one-year 
washout-period and having stents during two-year intake-period (January 1, 2006–
December 31, 2007). Annual claims records were aggregated for each patient to produce 
patient-speciﬁ c information on total utilization, costs and anti-thrombolytic use. We 
examined the pattern of anti-thrombolytic use according to types of the ﬁ rst stents(group 
I as using drug-eluting stents [DES], group II as using bare-metal stents [BMS]) and types 
of revascularization method (group A-DES, group B-BMS, group C-balloon, group 
D-CABG). RESULTS: There were 19,120 subjects identiﬁ ed as STEMI patients. Each 
STEMI patient had 8.7 outpatient visits, 1.1 admission per year. The total costs for 
treating STEMI in the nation was estimated as Korean-won (KRW)106,666million. 
The per-capita insurance-covered costs were KRW3,721,390. Those increased until 
the age of 74 years and reduced after the age of 75 years. The annual number of claims 
in tertiary hospital was slightly fewer than secondary hospitals (13,303 vs. 13,730), 
but insurance-covered costs/claim in tertiary hospital were higher than those in second-
ary hospitals by KRW1,493,051. The duration of using Cilostazol from the ﬁ rst 
stenting to revascularization in group I was 79.12 days, while GroupII was 73.44 
days. The use of Cilostazol was longer in group IA (95.8 days) or IC (89.18 days) 
than group IIA (62.15 days) or group IIC (61.33 days). CONCLUSIONS: In Korea, 
the burden of illness for AMI is a signiﬁ cant issue. Cilostazol was used longer when 
DES were used at ﬁ rst stenting compared to BMS. Whether the longer usage of Cilo-
stazol results in better outcome needs further research. 
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CLINICAL OUTCOMES FROM PHARMACIST-MANAGED 
ANTICOAGULATION CLINICS (ACC) IN PRIMARY CARE SETTINGS IN 
SINGAPORE
Lee JYC1, Koh LYJ1, Kong CM1, Bek E2, Xu S3
1National University of Singapore, Singapore; 2National Healthcare Group Pharmacy, 
Singapore; 3National Healthcare Group Pharmacy, Singapore
OBJECTIVES: Pharmacist-managed anticoagulation clinics (ACC) have been proven 
to provide positive outcomes in both overseas and local tertiary settings as part of a 
health-care team in caring for patients on warfarin therapy. However, currently, there 
is no published study on the effectiveness of pharmacist-managed ACC in the primary 
care settings in Singapore. Therefore, the primary objectives of this study were to 
determine the effectiveness of pharmacist-managed ACC in maintaining INR within 
the therapeutic range, and their associations with patient demographics. The second-
ary objective was to examine the incidence of warfarin-related adverse effects. 
METHODS: This was a retrospective, time-series study conducted in nine outpatient 
primary care clinics in Singapore from September to December 2009. All patients aged 
≥21 years with at least three visits with the ACC pharmacists within the ﬁ rst 12 months 
of physician referral were included in this study. Patient demographics and clinical 
outcomes, such as INR and incidence of warfarin-related adverse events, were col-
lected at ﬁ rst visit to ACC and at every 4-month interval for a total of 12 months. 
RESULTS: A total of 269 patients were under the care of ACC pharmacists from April 
2008 to May 2009, and of which 82 (30%) met the inclusion criteria. INR was 
maintained at therapeutic range throughout the 12-month period with minimal ﬂ uc-
tuations between each visit (P = 0.621). There was no association between INR and 
patient demographics except for intake of vitamins, supplements and herbal medica-
tions (P = 0.006) and change in medications (P = 0.039) at the 12th month. Docu-
mented warfarin-related adverse events included gingival bleeds (1; 1%), leg cramps 
(5; 6%), and swells (5; 6%). CONCLUSIONS: Pharmacist-managed ACC in the 
primary care settings in Singapore were effective in maintaining INR within the thera-
peutic range. The service also minimized the frequency of adverse events commonly 
associated with warfarin therapy. 
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PHYSICIAN-LEVEL CLASS EFFECT ON 90-DAY BLOOD PRESSURE 
VALUES: A META-ANALYSIS OF MULTILEVEL OBSERVATIONAL STUDIES 
OF VALSARTAN ANTIHYPERTENSIVE EFFECTIVENESS
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1University of Arizona College of Pharmacy Center for Health Outcomes and 
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OBJECTIVES: Blood pressure (BP) values in response to antihypertensive treatment 
are inﬂ uenced by both physician- and patient-level factors. We quantiﬁ ed summary 
estimates of variability in BP values attributable to a physician-level class effect across 
six observational studies. METHODS: We evaluated 90-day BP data on 14,116 
patients, in whom prior treatment failed or was not tolerated, who received valsartan-
based therapy for the treatment of hypertension. Data were collected during six 
consecutive prospective, observational, multi-center, pharmaco-epidemiologic studies 
conducted in Belgium between 2005 and 2009. Each study was designed to collect 
data from patients and their treating physicians. We applied a two-level hierarchical 
linear modeling method, using mixed-effects regression with residual maximum likeli-
hood estimation. From these data, intraclass correlation coefﬁ cients (ICC)s were 
calculated to quantify the variability in 90-day systolic BP (SBP) and diastolic BP (DBP) 
values attributable to within-physician variability in each study. We then completed 
a random-effects meta-analysis of ICC point estimates and variance from each study, 
to account for within- and between-study differences, and derived ICC summary 
estimates and 95% conﬁ dence intervals (CI). RESULTS: Summary estimates of abso-
lute reduction in 90-day SBP and DBP across studies were −18.17 mmHg (95% CI = 
−16.84 to −19.51 mmHg) and −9.73 mmHg (95% CI = −9.22 to −10.24 mmHg) 
respectively. ICCs for SBP ranged from 0.210 to 0.277, with a random-effects 
summary estimate of 0.238 (95% CI = 0.220 to 0.256; P < 0.0001; = 0.002; I2 < 
1%). ICCs for DBP ranged from 0.176 to 0.282, with a random-effects summary 
estimate of 0.255 (95% CI = 0.229 to 0.282; P < 0.0001; = 0.022; I2 = 45.69%). 
CONCLUSIONS: Considering within- and between-study differences in ICC, the 
average proportion of variance in 90-day SBP and DBP values attributable to a phy-
sician-level class effect was between 22.0% and 25.6%, and 22.9% and 28.2%, 
respectively. Further research is warranted to identify speciﬁ c and amenable physician-
level factors that contribute to higher BP values in response to antihypertensive 
treatment. 
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ROLE OF COMMUNITY PHARMACISTS IN HEALTH-RELATED 
EDUCATION AND COUNSELLING: VIEWS FROM GENERAL PUBLIC IN 
THE STATE OF PENANG, MALAYSIA
Hassali MA, Haddad M, Shaﬁ e AA
Universiti Sains Malaysia, Minden, Penang, Malaysia
OBJECTIVES: To explore general public’s awareness and perceptions toward the role 
of community pharmacists in the provision of health related education and counsel-
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ling. METHODS: A cross-sectional study design using convenience sampling tech-
nique was used in this study. A validated self-administered questionnaire using 5 point 
Likert scale was distributed to 440 respondents in the State of Penang, Malaysia. The 
Statistical Package of Social Science (SPSS Inc., Chicago, IL) for Windows version 12.0 
was used for all the statistical tests and a p-value of <0.05 was considered statistically 
signiﬁ cant. RESULTS: The result revealed that majority of the respondents (69.3%), 
understand the roles of community pharmacists in patients’ education and counselling. 
More than half of them (66.3%) are aware of the availability of medical counselling 
provided by community pharmacists. Majority of the respondents (66.8%), are aware 
that community pharmacists are well-trained to provide medical education and counsel-
ling. On the other hand, less than half of the respondents (46.6%) perceive that phar-
macists are the best people to provide medical education and counselling to the public. 
About 70% of the respondents had mentioned that the pharmacist will ask them about 
their medical conditions and allergies before recommending any medications. Respon-
dents also found that: pharmacists are very approachable for giving medical education 
and counselling (56.4%); community pharmacists help them to explain the misconcep-
tions that they had in health care (59.0%); they have changed for healthier lifestyles 
after being exposed to medical education and counselling by community pharmacists 
(58.2%). CONCLUSIONS: The present study also found that the respondents are 
generally well aware and satisﬁ ed toward the medical education and counselling 
provided by community pharmacists in the state of Penang, Malaysia. 
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MEDICAL MALPRACTICE AND LITIGATION: WHAT DOES THIS MEAN 
FOR THE COST-EFFECTIVENESS OF DIAGNOSING CHEST PAIN?
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OBJECTIVES: To determine the effect of including the costs and risks of medical 
negligence claims on the results of a cost-utility model of diagnostic strategies for 
patients with chest pain presenting at the Emergency Room. Coronary computed 
tomography (CT) has been proposed as an initial screening technique for patients at 
low risk of coronary artery disease, because it may allow earlier discharge and cost 
savings compared with stress-based tests such as exercise single-photon emitting 
computed tomography (SPECT) or exercise echocardiography (E x E). METHODS: 
A decision-analytic model was designed to calculate the expected costs and health 
outcomes at 12 months for patients at low risk of coronary artery disease presenting 
at the Emergency Room with chest pain. Published data was used to predict the 
accuracies of the diagnostic tests. Costs were calculated from the perspective of the 
Australian health system, and a rate (30%) and cost of litigation ($160,000) was 
included for false negative diagnoses that incurred an event within the time frame. 
RESULTS: ExE was the least costly strategy in the base case analysis. The results are 
sensitive to changes in the cost and likelihood of litigation, because these costs are 
high relative to the other costs in the model. At a 30% claim rate, if the expected 
payout for litigation is <$150,000, CT is the most cost-effective option, with lower 
costs and higher QALYs. The ICERs are high because the differences in QALYs are 
small. In contrast, at the expected cost of litigation in the United States ($1,000,000), 
the strategy with lowest event rate (SPECT) is the least costly strategy. CONCLU-
SIONS: Litigation costs for medical negligence can change the outcomes of cost-utility 
analyses. We consider that these should be assessed and included when an analysis is 
undertaken from the societal perspective. 
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A SURVEY EXPLORING KNOWLEDGE AND PERCEPTIONS OF GENERAL 
PRACTITIONERS TOWARD THE USE OF GENERIC MEDICINES IN THE 
NORTHERN STATE OF MALAYSIA
Hassali MA, Shaﬁ e AA
Universiti Sains Malaysia, Minden, Penang, Malaysia
OBJECTIVES: To evaluate knowledge and perceptions of Malaysian general medical 
practitioners (GPs) on issues surrounding the safety, efﬁ cacy, and quality of generic 
medicines. METHODS: A postal cross-sectional survey involving registered GPs (n = 
325) in Penang, Malaysia was undertaken. The questionnaire consisted 23-item and 
validated accordingly before it been sent to the GPs. At the end of the survey period, 
a total of 87 GPs responded to the survey (Response rate of 26.8%). RESULTS: The 
majority of the respondents (85.1%) claimed that they actively prescribed generic 
medicines in their practice. On the other hand, only 4.6% of the respondents correctly 
identiﬁ ed the Malaysia’s National Pharmaceutical Control Bureau’s bioequivalence 
standard for generic products. There were misconceptions among the respondents 
about the concepts of “bioequivalence,” “efﬁ cacy,” “safety,” and “manufacturing 
standards” of generic medicines. GPs in this survey believed that a standard guideline 
on brand substitution process, collaboration with pharmacists, patient education and 
information on safety and efﬁ cacy of generic medicines were necessary to ensure 
quality use of generics. Furthermore, advertisements and product bonuses offered by 
pharmaceutical companies, patient’s socio-economic factors as well as credibility of 
manufacturers were factors reported to inﬂ uence their choice of medicine. CONCLU-
SIONS: As a conclusion, although it appeared that GPs have largely accepted the use 
of generic medicines, they still have concerns regarding the reliability and quality of 
such products. GPs need to be educated and reassured about generic products approval 
system in Malaysia concerning bioequivalence, quality, and safety. 
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ASSOCIATION BETWEEN HOSPITAL PROCESS PERFORMANCE AND 
OUTCOME OF PATIENTS WITH ACUTE MYOCARIDAL INFARCTION
Tan CH1, Tam SC2, Yang MC1
1National Taiwan University, Taipei, Taiwan; 2Chang Jung Christian University, Tainan County, 
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OBJECTIVES: Much literature has proved that process of care in acute myocardial 
infarction (AMI) patients has signiﬁ cant effect on mortality and prognosis. However, 
little study has discussed about the association between hospital process performance 
and patients’ outcome. The objective of this study was to investigate the association 
between hospitals care process and patients’ outcome while controlling for potential 
confounders, including coexisting conditions, severity of illness and process perfor-
mance of hospitals in Taiwan. METHODS: The claimed data came from the National 
Health Insurance Research Database for inpatient treatment for AMI in 2007 to 2008. 
Totally 109 hospitals and 899 patients were enrolled in this study. Main outcome 
measures were 6 ACC/AHA class I guideline-recommended treatments and the correla-
tion between hospitals’ individual care processes performance and 30-day mortality 
rate of patients. We tested the association between the process and outcome for each 
hospital by using a hierarchical linear model (HLM) for each process measure. 
RESULTS: Over all, the average eligible rate among six ACC/AHA guideline-recom-
mended treatments was 42.38%. The eligible rate of reperfusion was signiﬁ cantly 
different between public, nonproﬁ t and private hospitals (P = 0.0004). Factors highly 
correlated with 30-day mortality rate of patients included using aspirin (OR = 0.97, 
P < 0.0001), using lipid-lowering agents (OR = 0.99, P = 0.005) and having reperfu-
sion (OR = 0.99, P = 0.05) at admission. CONCLUSIONS: Signiﬁ cant associations 
between hospital care process and patients’ outcomes were found. The results sup-
ported the use of guideline-based performance measures which can help improving 
hospital quality. 
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ST. VINCENT’S PRIVATE HOSPITAL VENOUS THROMBOEMBOLISM 
PREVENTION PROJECT: ANALYSIS OF REDUCED COST AND IMPROVED 
CLINICAL OUTCOMES
Duff J1, Walker K1, Lee J2, Stratton C2
1St Vincent’s Private Hospital, Sydney, NSW, Australia; 2Sanoﬁ -Aventis Australia, Sydney, NSW, 
Australia
OBJECTIVES: Prophylaxis with a low molecular weight heparin (LMWH) such as 
enoxaparin or a low-dose unfractionated heparin (LDUH) in high risk medical and 
surgical patients is consistent with the recommendations made by the American 
College of Chest Physicians Eighth Conference on Antithrombotic and Thrombolytic 
Therapy. While these guidelines present strong evidence to support the use of prophy-
laxis to prevent venous thromboembolism (VTE), they are not always adhered to in 
clinical practice. The St. Vincent’s Private Hospital VTE Prevention Project aimed to 
improve compliance with best practice prophylaxis in hospitalized patients. An audit 
of the rates of prophylaxis was conducted over a 12-month period as part of this 
project. The aim of this analysis was to determine whether the measures implemented 
as a result of the St. Vincent’s project translated into cost savings and improved clinical 
outcomes. METHODS: A decision-analytic model was constructed using audit data 
from 21,942 medical and surgical patients admitted to St. Vincent’s who received 
either enoxaparin 40 mg daily, unfractionated heparin (UFH) three times daily (TID) 
or no prophylaxis. The rate of prophylaxis at baseline was compared with that at the 
end of the audit for each prophylaxis regimen. Clinical trial data was used to estimate 
the incidence of VTE (deﬁ ned as deep vein thrombosis [DVT] and pulmonary embo-
lism [PE]), and major bleeding. RESULTS: As a result of the measures introduced to 
improve adherence to best practice, we estimated 13 fewer deaths, 84 fewer symp-
tomatic DVTs, 19 fewer symptomatic PEs and 512 fewer hospital bed days over 
baseline, across all medical and surgical patients. We also estimated that overall costs 
were reduced by $245,439 over 12 months. CONCLUSIONS: Improved adherence 
to best practice in VTE prophylaxis in the Australian clinical setting is likely to result 
in fewer deaths, VTE events and signiﬁ cant overall cost savings. 
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THE EVALUATION OF CARE PATHWAYS AS A COMPLEX 
INTERVENTION: APPLICATION OF A METHODOLOGICAL 
FRAMEWORK
Panella M
Amedeo Avogadro University, Novara, Italy
OBJECTIVES: To assess the extent to which the development steps of the evaluation 
of care pathways (CP) can be represented in the framework for the design and evalu-
ation of complex interventions. METHODS: The framework is composed by ﬁ ve 
phases: theoretical (pre-clinical), identiﬁ cation of components of the intervention 
(phase I), deﬁ nition of trial and intervention design (phase II), main trial execution 
(phase III), promoting effective implementation (phase IV). RESULTS: The framework 
was applied to the evaluation of CP for strokes. Pre-clinical phase was aimed in 
synthesizing the evidences: three reviews were selected and showed that CP are theo-
retically applicable in stroke care and that mortality should be the main outcome to 
be analyzed. Phase I was done through a descriptive pilot. A total of 253 consecutive 
patients admitted for strokes in 29 hospitals were analyzed. Overall in-hospital stroke 
mortality was 19.76%. Stroke teams (OR = 0.25; P = 0.025), antithrombotic therapy 
(OR = 0.26; P = 0.009) and complications (OR = 6.40; P < 0.001) were independent 
predictors of in-hospital mortality. Therefore these variables were selected as 
